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Abstract
Methotrexate has been applied clinically for juvenile idiopathic arthritis (JIA) treatment for decades. It is recommended for 
use globally, according all modern guidelines. Despite the fact that fibrosis molecular mechanisms as well as methotrexate (MTX) 
elimination and fibrosis indexes were studied a lot there is still not enough information for adolescence. Adiponectin, fibroblast 
growth factor and fibrosis indexes in adolescents with JIA treated with methotrexate were studied in this work. 
The aim was to study dynamics of molecular-cellular mechanisms activation of fibrotic processes development in the liver 
in adolescents with juvenile idiopathic arthritis treated with methotrexate. 
Materials and methods: A total of 68 children with juvenile idiopathic arthritis, were enrolled in the study. 25 boys 
(36.8 %) and 43 girls (63.2 %) were examined. Children were divided into three groups in accordance with the methotrexate dose. 
The following data were analyzed: ESR (mm/hour), C-reactive protein (mg/l), Hemolytic activity (CU), circulating immune com-
plexes, (g/l), ALT (U/l), AST (U/l), Adiponectin (mcg/ml), BFGF (pg/ml), APRI index, FIB-4 Score. 
Results: According to our results when patients start using MTX they have significantly positive effect. Therefore, when 
analyzing all parameters liver pathologies may occur before MTX use. When MTX used, its proinflammation and antifibrotic effects 
lead to normalization of all organs and systems, as well as joints and liver. Also, long-term MTX use can lead to adverse effects. 
Conclusions: So, it is important to control possible liver disorders in adolescence treated with MTX. According to our study 
results we find out that there are decreasing of liver damage parameters in patients which started using MTX.
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Juvenile idiopathic arthritis (JIA) is the most common chronic disease of childhood. One in 
1,000 children is affected by the various subtypes of JIA. Methotrexate (MTX) is a cornerstone of 
therapy worldwide for JIA, yet there remains vast variability in drug dosing and administration, 
as well as unpredictable outcomes on the drug [1]. Methotrexate (4-amino-10-methylpholic acid) is 
commonly administered orally as a single weekly dose. MTX dosage is clearly regulated by mod-
ern treatment guidelines. After oral administration, MTX is absorbed in the proximal jejunum by 
the proton-coupled folate transporter, which transports reduced folates and MTX [2]. MTX max-
imum plasma concentrations are between 0,3 and 1,6 µmol/L, and occur at up to two hours after 
administration [3]. Also MTX can distribute to the synovial fluid with comparable levels to those 
found in plasma [4]. MTX side effects on the gastrointestinal tract are associated precisely with 
the antagonism of MTX and folate. Adding folic or folinic acid to therapy almost eliminates such 
side effects as nausea, vomiting, diarrhea, or stomatitis [3]. Manifestations of nausea and diarrhea 
are more often observed with oral administration of MTX [5]. Major elimination route of MTX is 
renal excretion constitutes. MTX is subject to first-pass metabolism in the liver and is converted 
to 7-hydroxymethotrexate, which is a major metabolite of MTX [6]. MTX in small proportion is 
excreted in the bile and some enterohepatic recycling also happens [3, 6, 7]. The plasma half-life of 
low dose MTX varies from 4.5 hours to 10 hours [4]. Hepatotoxicity is one of the main side effects 
of MTX in the JIA treatment. Slight increase in aminotransferases level, less commonly hepatic 
steatosis, fibrosis and cirrhosis are most common manifestations [8]. 
The precise mechanisms of MTX toxicity are still not clear. It was suggested that MTX 
hepatotoxicity may result from a depletion of hepatic folate stores and the accumulation of MTX 
polyglutamates in the liver [9]. However, folate supplementation has been associated with a reduced 
incidence of hepatic adverse effects (elevated transaminases) induced by MTX treatment [10].
MTX-related hepatic fibrosis may be mediated through an adenosine pathway. MTX was 
shown to enhance the release of adenosine from cultured hepatoma cells. Adenosine binds to the 
adenosine A2A receptor on hepatic stellate cells which is the principal fibrogenic cell type in the 
liver, and promotes collagen production [11, 12]. 
Moreover, MTX is known to interfere with the generation of methionine from homocyste-
ine. Excess homocysteine can induce endoplasmic reticulum stress and promote fat accumulation 
in the liver. Homocysteine can also activate proinflammatory cytokines and hepatic stellate cells, 
leading to liver fibrosis [13]. MTX-induced hepatic damage may be related to reactive oxygen spe-
cies generation. MTX was shown to cause oxidative tissue damage by increasing lipid peroxidation 
in the liver tissue and decreasing the level of antioxidant enzymes [14].
Fibrosis can cause impaired liver function due to changes in the tissue microenvironment, 
various growth factors synthesis, inflammatory cytokines functioning, a violation of the liver nor-
mal structure as a result of changes in the distribution and proportions of febrile collagen.
Despite the significant compensatory liver potential in childhood, it is important to prevent 
of steatosis and fibrosis development in the future. Adiponectin is the most common protein se-
creted by white adipose tissue. It circulates in the blood, and its concentration in serum is inversely 
proportional to fat mass. The wide distribution of adiponectin receptors in peripheral tissues and 
organs allows adiponectin to exert a pleiotropic effect on the general body metabolism. In addi-
tion to the well-known anti-diabetic, anti-atherogenic and anti-inflammatory properties, have been 
obtained data on the direct effect of adiponectin on non-alcoholic fatty liver disease development.
The study of the risk of developing fibrosis is possible including use of trigger factors for 
the development of fibrosis. Fibroblast growth factor (FGF) showed a potential effect on tissue 
repair and regeneration [15, 16]. It was first identified as a protein capable of stimulating fibroblast 
proliferation, and it is now known that the group of these factors includes 22 members. FGFs per-
form multiple functions by binding and activating fibroblast growth factor receptors (FGFRs), and 
the main signalling pathway is FGFR stimulation leading tissue repair and regeneration [17, 18]. 
Fibroblast growth factor receptors 1, 2, and 4 are expressed in the liver, with FGFR4 exclusively in 
hepatocytes [19, 20]. FGF1 and FGF2 are produced during hepatocyte replication and are mitogens 
for both endothelial and stellate liver cells [21].
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Despite the fact that treatment with methotrexate JIA is the key, it makes sense to study the 
balance between its positive and negative effects, including finding out the risk of fibrosis.
The aim was to study dynamics of molecular-cellular mechanisms activation of fibrot-
ic processes development in the liver in adolescents with juvenile idiopathic arthritis treated 
with MTX.
2. Materials and methods
The study group included JIA patients, a total of 68 children 25 boys (36.8 %) and 
43 girls (63.2 %). The average age of patients was 13.3±0.3 years. This study was carried out 
from 2017 to 2019.
Children were treated at the Cardiac-Rheumatology Department, State Institution “Institute 
for the Protection of Children and Adolescents’ Health”, Academy of Medical Sciences of Ukraine 
with Juvenile idiopathic arthritis. The diagnosis juvenile idiopathic arthritis was established in ac-
cordance with EULAR recommendations relevant at the time of the study. Treatment was carried 
out according to the same recommendations for all children. Informed consents’ from all patients 
were obtained. 
This work complies with ethical standards and it was approved by ethical committee of 
Kharkiv medical academy of postgraduate education from the 18th of February 2020, protocol No. 1. 
This work was carried out according to the Helsinki Declaration.
Inclusion criteria’s were boys and girls from 10 till 18 years old with JIA (with oligoarthritis 
and polyarthritis) treated with MTX or patients whom MTX were prescribed, but they did not re-
ceived it yet on the moment of the study start. 
Exclusion criteria’s: children with chronic liver pathology, gastrointestinal, genetic and en-
docrinal disorders which occurred before JIA were diagnosed, children with uveitis. All examined 
patients had no viral hepatitis.
All adolescents underwent laboratory tests: clinical blood count, liver tests (AST (U/L), 
ALT (U/L)), acute phase indicator (C-reactive protein (mg/l)), Hemolytic activity (CU), circulating 
immune complexes, (g/l), Adiponectin (mcg/ml), BFGF (pg/ml). Abdominal organs ultrasound 
examination, joints ultrasound, and joints X-Ray were provided. 
Level of adiponectin in the blood was determined by an enzyme-linked immunosorbent 
assay using the Human Adiponectin ELISA reagent kit, manufactured by BioVendor.
Determining the level of BFGF in the blood was carried out by an enzyme-linked immuno-
sorbent assay using the Human bFGF ELISA reagent kit, manufactured by Elabscience. 
Fibrosis indexes were calculated with Microsoft Excel program using standard formulas:
APRI index (AST to Platelet Ratio Index) was calculating using formula: 
[(AST/ULN AST)×100]/Platelets (109/L)].
FIB-4 score index (Fibrosis 4 Score) was calculated using following formula: 
(Age×AST)/(Platelets×(sqr (ALT)).
Adiponectin was studied to assess the risk of liver steatosis. Adiponectin was measured ac-
cording to the instructions by ELISA. To assess the risk of liver fibrosis, the basic fibroblast growth 
factor (BFGF) was studied. We measured it according to the instructions by ELISA.
Children were divided into three groups according to the dose of methotrexate per 1 m2. 
The first group (0 (n=18)) included children with JIA who had just been appointed MTX and they 
had not received it yet. In the second (1 (n=21)) were children who receive MTX less than 12.5 mg, 
third (2 (n=25)) included ones who had dose more than 12.5 mg. The distribution of indicators was 
carried out in accordance with an average value of 12.5.
Statistical analysis was carried out with software package Statistica 6.0. Before sta-
tistical processing, all data was checked for normal distribution. Normal distribution data 
were analyzed with a Pearson correlation method, a Spearman correlation was used for not 
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normally distributed data relationships. One-way ANOVA was used to analyze differences 
between groups. LSD test was used to calculate the statistical significance. Differences were 
considered significant at p <0.05.
3. Results
The proportions of gastrointestinal tract disorders associated in the study groups treated 
with MTX were as follows: nausea – 42.1 %, belching – 3.2 %, epigastric pain – 51.0 % pain 
in the pyloroduodenal zone – 41.4 %, pain in the right hypochondrium – 37.7 %, abdominal 
pain – 21.7 %. Liver size increase during palpation was found in 73.8 % of adolescents. The 
presented data cannot be the criteria for the diagnosis of fibrosis and steatosis. It seems to be 
of particular importance to be able to differentiate, based on biomarker analysis, between risk 
of steatosis and fibrosis development. Thus we analyzed biochemical parameters (Table 1) and 
their correlations. 
Table 1
Laboratory parameters value in adolescents with JIA, taking into account the dose of MTX per 1 m2
Grouping 0 1 (˂12,5) 2 (˃12,5) 
Indicator n=18 n=21 n=25
ESR mm/hour 5.33±1.45 3.67±0.46 6.04±1.26
Hemolytic activity, CU 0.99±0.04 0.94±0.1 1±0.04
Circulating immune complexes, g/L 1.17±0.062 1.33±0.099 1.21±0.045
ALT U/L 20.9±1.97*0,1 31.1±2.37 25.8±1.79
AST U/L 25.1±2.25*0,1 32.4±2.39 29.9±2.09
APRI index 0.29±0.031 0.36±0.04 0.37±0.03
FIB-4 Score 0.24±0.028 0.30±0.023 0.29±0.017
Adiponectin(mcg/ml) 1.53±0.144 1.51±0.08 1.47±0.12
BFGF(pg/ml) 6876.4±338.05 7517.3±209.7 7134.9±228.4
Note:*0,1 – the presence of a statistically significant difference between groups and figures is indicated; it is noted between which 
particular groups this difference is present p˂0,05 
 
In the same group correlation of BFGF with the degree of functional disorders of the joints 
(r=0.496, p=0.036) were found. Thus, the more disorders in the joints, the more active are the pro-
cesses associated with collagen metabolism as a result of JIA. An increase in the level of BFGF in 
the central bloodstream can lead to the activation of fibrotic processes in various organs and tis-
sues, and especially in the liver. This may be a reflection of the increased risk of sclerotic processes 
in the liver.
Positive correlation between BFGF level and hepatomegaly according to ultrasound data 
(r=0.752, p=0.014) may indicate both the spread of autoimmune inflammatory process to the liver 
and fibrosis. 
Alterative processes in the liver associated with autoimmune inflammation are confirmed 
by the presence of a positive correlation between ALT and BFGF (r=0.512, p=0.029). It is possible 
to assume that, on the one hand, hepatocyte necrosis takes place in the liver and at the same time 
proliferative processes occur in the vascular component of the organ stroma, which can enhance the 
acceleration of the fibrosis process. This is confirmed by the revealed positive correlation between 
the content of BFGF and the FIB-4 Score index (r=0.546, p=0.019).
In this study, no correlation was found between platelets level, AST and BFGF, which in-
dicates that their action is different, although not detected with statistics methods, which directed 
towards to fibrotic processes development, since the combination of these indicators in fibrosis 
index gives a positive correlation with BFGF. Inflammatory process activity also presented in this 
study with decrease hemolytic activity level (r=–0.878, p=0.021) and an increase in BFGF level in 
the central bloodstream, which is typical for autoimmune disorders.
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A positive correlation of adiponectin and BFGF (r=0.577, p=0.019) may reflect an increase 
in its anti-inflammatory effect upon activation of collagen synthesis, in addition, adiponectin in-
hibits the adhesion of monocytes to vascular endothelial cells.
On the other hand, an increase in adiponectin levels with increased fibrotic activity may be 
associated with a steatosis risk due to visceral adipose tissue development.
BFGF correlations in group 1 were presented with statistically significant dependence with 
CIC (r=0.476, p=0.039) which is associated with an increase of autoimmune process characteristic 
activity of the inflammation phase. In this group also, there were no statistically significant cor-
relations with BFGF, which was noted in the previous group and negative correlations were found 
with AST (r=–0.568, p=0.011) and the APRI index (r=–0.647, p=0.002), which may indicate a 
rather low risk of fibrosis in this group. This may be due to the antifibrotic effect of MTX, both on 
the joints and on the liver.
Group 2 did not show statistically significant correlations. That is, the lack of correlations 
defined in the previous groups, possibly indicates effective treatment, a decrease in the activity of 
inflammation and fibrosing.
4. Discussion
Our findings showed that although a relatively large proportion of patients with JIA report-
ed symptoms of nausea and epigastric pain, relatively few of these patients could in fact be diag-
nosed with steathosis or fibrosis. A large proportion of patients with JIA failed to achieve predicted 
values for the parameters of abnormal liver tests values. These findings are consistent with those of 
large population studies which suggest that taking folic acid reduces the negative effects of MTX 
when taken orally. These findings are consistent with those of large population studies [3].
Despite the fact that fibrosis molecular mechanisms as well as MTX elimination and fi-
brosis indexes were studied a lot there is still not enough information for adolescence. According 
to our results when patients start using MTX they have significantly positive effect. Therefore, 
when analyzing all parameters liver pathologies may occur before MTX use. When MTX start-
ed its proinflammation and antifibrotic effects lead to normalization of all organs and systems, 
as well as joints and liver. Also, long-term MTX using can lead to MTX hepatotoxicity caused 
by MTX polyglutamates accumulation in the liver [9] or folate supplementation [10] which was 
reported by others.
 So, it is important to control possible liver disorders in adolescence treated with MTX. 
According to our study results we find out that there are decreasing of liver damage parameters in 
patients which started using MTX.
The coexistence of antifibrotic effects of MTX, its gastric side effects and risk of liver ste-
atosis and fibrosis development in patients with JIA requires further studies aiming to determine 
the mutual relationship of these phenomena and their association with liver risk. MTX-related 
hepatic fibrosis through an adenosine pathway was reported [11]. Homocysteine can also activate 
proinflammatory cytokines and hepatic stellate cells, leading to liver fibrosis [13]. MTX-induced 
hepatic damage may be related to reactive oxygen species generation [14].
To apply this knowledge in the daily practice of a doctor further studies are necessary. BFGF 
may be a valuable complement to liver tests. Additionally, it can help identify abnormal liver func-
tioning, which may be associated with the reported symptoms.
Study limitations
We are aware that the small sample size is a limitation of the study. Despite the fact that liver 
biopsy remains diagnostic standard it is invasive method and cannot be used to perform popula-
tion screening and assess the course of the disease in patients with diagnosed steatosis or fibrosis. 
Therefore, liver biopsy was not performed, and we cannot definitively exclude liver fibrosis and 
steatosis. However, morphological study cannot be provided in pediatrics as a screening method. 
Our study comprised mostly adolescence with JIA treated with MTX without any other serious co-
morbidities and our results should not be extrapolated to the general population. On the other hand, 
the strength of our results is that we recruited adolescences with JIA without other serious chronic 
diseases, with different dose of MTX.
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Prospects for further research 
In the future, it is planned to analyze the dependence of BFGF in patients with JIA with 
other parameters. It is also planned to study the correlation of the degree of differentiation of BFGF 
with hepatocyte grows factor. BFGF data analyzing with routine laboratory and instrumental stud-
ies is appropriate for the timely determination of the risks of developing irreversible pathological 
changes in the liver during JIA treatment with MTX.
5. Conclusions
In patients with JIA, the activity of systemic inflammation increases even before the 
start of treatment, as evidenced by a statistically significant correlation of BFGF level in group 
of patients who did not receive MTX. This indicates a close relationship between the intensi-
ty of the inflammatory process and collagen synthesis activation, which can further provoke 
liver fibrosis.
In patients who started receive MTX alterative processes in the liver associated with au-
toimmune inflammation can be reduced firstly according to obtained data. Adequate treatment 
of MTX in accordance with modern guidelines reduces the risk of fibrosis and the activity of the 
inflammatory process.
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